FAIRFIELD, Conn., July 19, 2017 -- Acme United Corporation (NYSE:ACU) will release its financial results for the Second Quarter of 2017 on Tuesday, July 25, 2017, at 9:00 a.m. EDT.
A conference call to discuss these results will be broadcast over the Internet on Tuesday, July 25, 2017, at 12:00 p.m. EDT. To listen or participate in a question and answer session, dial 800-768-6544. International callers may dial 785-830-7990. Access to the live webcast of the conference call can be found in the Investor Relations section of the Company’s website, www.acmeunited.com. A replay may be accessed under Investor Relations, Audio Archives.
Acme United Corporation is an innovative supplier of cutting devices, measuring instruments, and safety products for school, home, office, hardware and industrial use. Its leading brands include Westcott®, Clauss®, Camillus®, Cuda®, PhysiciansCare®, First Aid Only®, Pac Kit®, DMT® and Spill Magic®.
Contact Acme United Corporation Paul G. Driscoll, 203-254-6060 [email protected]


Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



